These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38018328)

  • 1. Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
    O'Sullivan M; Jones AM; Mourad A; Haddadin Y; Verma S
    J Viral Hepat; 2024 Feb; 31(2):66-77. PubMed ID: 38018328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use drugs: Real-world outcomes.
    O'Sullivan M; Jones AM; Gage H; Jordan J; MacPepple E; Williams H; Verma S
    Liver Int; 2020 May; 40(5):1021-1031. PubMed ID: 32048798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
    Scherz N; Bruggmann P; Brunner N
    Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
    Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
    Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
    Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
    Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
    Bartlett SR; Wong S; Yu A; Pearce M; MacIsaac J; Nouch S; Adu P; Wilton J; Samji H; Clementi E; Velasquez H; Jeong D; Binka M; Alvarez M; Wong J; Buxton J; Krajden M; Janjua NZ
    Clin Infect Dis; 2022 Mar; 74(4):575-583. PubMed ID: 34125883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
    Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
    Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    Wolfson-Stofko B; Hirode G; Vanderhoff A; Karkada J; Capraru C; Biondi MJ; Hansen B; Shah H; Janssen HLA; Feld JJ
    J Viral Hepat; 2024 May; 31(5):240-247. PubMed ID: 38385850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
    Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
    Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
    BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
    Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
    Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.